Last Updated: 12 February 2025
Harrison.ai, a leading global healthtech company specializing in AI-powered medical diagnostics, has raised $112 million in a Series C funding round to accelerate its expansion into the United States. The investment will also support the company’s continued growth across the UK, EMEA, and APAC markets. This funding round ranks among the largest in the medical AI space in the past year.
The round was co-led by Aware Super, ECP, and Horizons Ventures, with additional participation from Australia’s National Reconstruction Fund Corporation (NRFC), Ord Minnett, Wollemi Capital Group, and existing investors like Blackbird Ventures and Alpha JWC Ventures. With this latest investment, Harrison.ai’s total capital raised now exceeds $240 million.
As healthcare systems worldwide grapple with a shortage of skilled professionals, Harrison.ai’s AI-driven tools are designed to increase clinician capacity, enhance operational efficiency, and improve early disease diagnosis.
Currently, 1.5 million skilled clinicians are needed globally, and in the United States, there are just 11 radiologists per 100,000 people, according to the Association of American Medical Colleges. More than two-thirds of the world’s pathologists are concentrated in only 10 countries. This disparity in medical resources makes AI-powered diagnostics a critical solution to improving healthcare access.
“The growing demand for equitable and effective healthcare calls for advanced systems like AI to enhance human diagnostics and address disparities in access to care. Harrison.ai meets this need by developing clinical-grade AI models designed to improve capacity. We look forward to bringing our life-saving technology to healthcare systems in the U.S. and continuing our expansion across the globe.”
Dr. Aengus Tran, Harrison.ai Co-Founder and CEO
Harrison.ai’s technology assists clinicians in detecting signs of cancer and other serious illnesses earlier by analyzing CT scans, X-rays, and pathology slides. Its solutions have already demonstrated significant impact, particularly in early lung cancer detection.
Radiologists using Harrison.ai’s AI-driven tools have achieved a 45% increase in diagnostic accuracy. Studies indicate that its AI for chest radiography could have enabled 32% of lung cancer cases to be diagnosed an average of 16 months earlier. Additionally, the technology has increased the proportion of treatable-stage cancer detections by over 26%.
The company’s radiology solution, Annalise.ai, is currently used by 1 in 2 radiologists in Australia and processes scans for over 131 public hospitals and 45 Trusts in the UK. It also powers all CT Brain scans in Hong Kong’s public A&E system and was recently selected by Denmark’s public healthcare system.
As part of its expansion, Harrison.ai is establishing a North American headquarters in Boston to focus on scaling U.S. operations and growing its customer base. The company has already achieved 12 FDA clearances, with one of its CT Brain AI algorithms receiving FDA Breakthrough Device Designation and Medicare reimbursement approval through the New Technology Add-on Payment (NTAP) program.
Additionally, Harrison.ai has developed Harrison.rad.1, a vision-language AI model for radiology, which is now accessible to researchers, industry partners, and regulators. The company has also been invited to participate in the Healthcare AI Challenge hosted by Mass General Brigham, alongside Microsoft, OpenAI, and Google, to assess AI applications in healthcare.
Founded in 2018, Harrison.ai is a global healthcare technology company dedicated to scaling medical diagnostic capacity through AI-powered solutions. Its flagship products, Annalise.ai (radiology) and Franklin.ai (pathology), are used in hospitals and private clinics across APAC, EMEA, the UK, and the U.S..
Harrison.ai’s funding journey has been backed by major investors, including Horizons Ventures, Aware Super, Blackbird Ventures, Alpha JWC Ventures, and NRFC.
“Harrison.ai’s ability to harness the rapidly evolving opportunities out of digitization and AI is remarkable and we look forward to supporting their long-term application to the healthcare sector.”
Alvin Chan, Portfolio Manager – Direct Equities at Aware Super
With over $240 million in total funding, Harrison.ai is positioned as one of the most well-funded AI-driven medical technology companies globally.
